In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.
about
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cellsThe role of interleukin-12 and interferon-gamma in GVHD and GVL.Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomibIs human cell therapy research caught in a mousetrap?Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicityCell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.Pathophysiology of acute graft-versus-host disease: recent advances.Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.Cytokine Dysregulation in Acute Graft-versus-Host Disease.Graft-versus-leukemia effect and its clinical implications.Cytokine inhibitors and graft-versus-host disease.Cytokine Detection and Modulation in Acute Graft vs. Host Disease in Mice.IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
P2860
Q33707814-ECD90D9E-31B5-4817-B0C9-CFCA22BC0B09Q34025160-30931D54-6F69-4C7F-B3B0-966C8D23653AQ34332019-941552ED-133C-4B84-8E06-D3DD323969C2Q34556966-92D1B7E7-B21B-48CC-BD2F-828EA95A12F2Q34834459-001564D4-A82B-440B-A74D-93533B2452C4Q35158939-CB4B0F81-7CC0-41F1-8A05-6D8252C5F062Q35743830-DDB7E1A5-7D92-4B23-9364-CB3F412A305CQ35848453-2310E699-6DD4-4220-85E4-5674ED5C6012Q36015241-66B517F7-1120-49A6-AFEC-F70E0581F69EQ36156559-3F4BAA48-5835-417E-9DF1-D4882483FF76Q36401145-5DF8DE9E-A7E8-43F8-AC7D-0F745FBF18A5Q37157989-5E23EEFA-5ADE-4890-A03A-CF27F17EF9DDQ37211290-46189E3B-F492-47AB-935F-B0C21EFF5E18Q37388260-D3ED263A-E63A-40DE-B32C-C333695A03E3Q38896511-BEF00B22-6457-46BE-B727-78333AA48972Q40920988-5B338DEC-06DF-48A9-A209-2FA224FB4537Q40967676-742ABA6C-E5EC-46EE-95D5-8FD60E3CCDEDQ42029951-1E4A3EE5-70B0-4D89-8165-CBF70807B9DEQ42139164-70DCC597-A361-4F82-87B2-A969892DB2D9
P2860
In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
In vivo administration of inte ...... y and permits alloengraftment.
@ast
In vivo administration of inte ...... y and permits alloengraftment.
@en
type
label
In vivo administration of inte ...... y and permits alloengraftment.
@ast
In vivo administration of inte ...... y and permits alloengraftment.
@en
prefLabel
In vivo administration of inte ...... y and permits alloengraftment.
@ast
In vivo administration of inte ...... y and permits alloengraftment.
@en
P2093
P2860
P356
P1476
In vivo administration of inte ...... y and permits alloengraftment.
@en
P2093
P2860
P304
P356
10.1084/JEM.171.3.645
P407
P577
1990-03-01T00:00:00Z